Janssen Sciences Ireland Unlimited Company
60Patents
60Active
60Granted
53Portfolio score
Filing activity: Jan 19, 2007 → Jul 3, 2024
Most-cited patents
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US11020476B2 | Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV) | Chemistry; Metallurgy | 11 | Active |
| US11021692B2 | Hepatitis B virus (HBV) vaccines and uses thereof | Chemistry; Metallurgy | 8 | Active |
| US10611769B2 | RSV antiviral pyrazolo- and triazolo-pyrimidine compounds | Chemistry; Metallurgy | 5 | Active |
| US10377738B2 | Pyridone derivatives for the treatment of viral infections and further diseases | Human Necessities | 5 | Active |
| US10441589B2 | Combinations and methods comprising a capsid assembly inhibitor | Chemistry; Metallurgy | 3 | Active |
| US11208464B2 | GDF15 fusion proteins and uses thereof | Chemistry; Metallurgy | 2 | Active |
| US10301347B2 | Uracyl spirooxetane nucleosides | Chemistry; Metallurgy | 1 | Active |
| US10774088B2 | Simplified procedure for the preparation of darunavir | Chemistry; Metallurgy | 1 | Active |
| US11564921B2 | Regimens for treating HIV infections and AIDS | Human Necessities | 1 | Active |
| US10316043B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | Human Necessities | 1 | Active |
| US11389447B2 | Aqueous suspensions of TMC278 | Human Necessities | 1 | Active |
| US10953009B2 | Long term treatment of HIV-infection with TMC278 | Human Necessities | 1 | Active |
| US10765674B2 | Prevention of HIV-infection | Human Necessities | 1 | Active |
| US11713345B2 | Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof | Chemistry; Metallurgy | 1 | Active |
| US11104678B2 | Purine derivatives for the treatment of viral infections | Chemistry; Metallurgy | 0 | Active |
| US11702426B2 | Macrocyclic deaza-purinones for the treatment of viral infections | Chemistry; Metallurgy | 0 | Active |
| US10385054B2 | Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases | Human Necessities | 0 | Active |
| USRE50189E1 | Long term treatment of HIV-infection with TMC278 | General | 0 | Active |
| US10973801B2 | Capsid assembly modulator dosing regimen | Human Necessities | 0 | Active |
| US10822347B2 | Thieno[3,2-d]pyrimidines derivatives for the treatment of viral infections | Human Necessities | 0 | Active |
| US10501463B2 | Antibacterial cyclopenta[C]pyrrole substituted 3,4-dihydro-1H-[1,8]naphthyridinones | Chemistry; Metallurgy | 0 | Active |
| US11597704B2 | 2,4-diaminoquinazoline derivatives and medical uses thereof | Human Necessities | 0 | Active |
| US12275770B2 | Glucagon like peptide 1 (GLP1)-growth differentiation factor 15 (GDF15) fusion proteins and uses thereof | Chemistry; Metallurgy | 0 | Active |
| US12178815B2 | Regimens for treating HIV infections and aids | Human Necessities | 0 | Active |
| US11129834B2 | Combinations and methods comprising a capsid assembly inhibitor | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.